Meeting
2014 ASCO Annual Meeting
A phase I trial of of cixutumumab (C) (IMC-A12) and sorafenib (S) for treatment of advanced hepatocellular carcinoma (HCC).
Authors
Anthony B. El-Khoueiry
USC Norris Comprehensive Cancer Center, Los Angeles, CA
Anthony B. El-Khoueiry , Robert O'Donnell , Philip C. Mack , Suzette Blanchard , Nathan Bahary , Yixing Jiang , John Joseph Wright , Helen X. Chen , Heinz-Josef Lenz , David R. Gandara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT01008566
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 4105)
DOI
10.1200/jco.2014.32.15_suppl.4105
Abstract #
4105
Poster Bd #
192
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
A phase I trial of cixutumumab (C) (IMC-A12) and sorafenib (S) for treatment of advanced hepatocellular carcinoma (HCC).
First Author: Anthony B. El-Khoueiry
Poster
2018 ASCO Annual Meeting
Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma.
First Author: Changhoon Yoo
Poster
2011 ASCO Annual Meeting
Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
First Author: R. S. Finn
Poster
2019 Gastrointestinal Cancers Symposium
Phase I study of tramatinib combined with sorafenib in patients (pts) with advanced hepatocellular cancer (HCC).
First Author: Emilie Wang